MINDACT Clinical Trial

The MINDACT clinical trial was designed to test whether a molecular test of 70 genes (MammaPrint) is better than standard clinical/pathological tests at predicting which women with early stage breast cancer will benefit from receiving chemotherapy. More details on the trial can be found on the NCI website at http://www.cancer.gov/clinicaltrials/search/view?cdrid=526522&version=healthprofessional and from the manufacturer at http://www.agendia.com/pages/mindact/128.php. The trial is ongoing (in Europe). A recent publication from Germany suggests that the test may be better at grouping patients into 'low' and 'high' risk of recurrence than currently used tests (http://www.ncbi.nlm.nih.gov/pubmed/20383789). The MINDACT clinical trial was designed to test whether a molecular test of 70 genes (MammaPrint) is better than standard clinical/pathological tests at predicting which women with early stage breast cancer will benefit from receiving chemotherapy. More details on the trial can be found on the NCI website at http://www.cancer.gov/clinicaltrials/search/view?cdrid=526522&version=healthprofessional and from the manufacturer at http://www.agendia.com/pages/mindact/128.php. The trial is ongoing (in Europe). A recent publication from Germany suggests that the test may be better at grouping patients into 'low' and 'high' risk of recurrence than currently used tests (http://www.ncbi.nlm.nih.gov/pubmed/20383789).